EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Kate Bingham

Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech

SV Life Sciences Advisers

07:45 18:30 (645 mins)

Main agenda

Registration and Exhibition open

07:45 10:30 (165 mins)

Main agenda

Continental Breakfast

09:00 10:30 (90 mins)

Main agenda

Routes of commercialization

This session will explore different commercialization strategies for drugs in a variety of indications and geographies. Panelists will discuss market identification and access, working with KOLs and patient organizations, and post-approval followup.

09:00 10:30 (90 mins)

Main agenda

Applications of evidence-based medicine today

Panelists discuss how real world data is impacting clinical development today. This session will address identifying and developing sources of real-world data and the engagement of regulatory bodies in this new approach.

  • Panelist Athula Herath - Global Head, Real World Evidence Disease Epidemiology, Novartis

09:00 10:30 (90 mins)

Main agenda

Microbiome: Advancing the science with business

This session will discuss the role business has in developing the science of microbiome research. Identifying unmet medical needs, acting as collaboration leaders, and funding primary research are just some of the ways industry is leading this cross-indication area of research.

10:00 18:30 (510 mins)

Main agenda

One-to-one Meetings

10:45 11:15 (30 mins)

Main agenda

Welcome and Opening Remarks

  • Speaker Anna Chrisman - Group Managing Director, EBD Group
  • Speaker Ramona Pop - Senator, Economics, Energy and Public Enterprises
  • Speaker David Thomas - Senior Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)

11:15 12:30 (75 mins)

Main agenda

Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech

Biotech has thrived because of the collaborative nature of its business model. The plenary session will address the new walls being erected within the industry, in policy, business, and science, which will require the same cooperation to break down.

  • Moderator Kate Bingham - Managing Partner, SV Life Sciences Advisers

12:00 14:00 (120 mins)

Main agenda

Luncheon

13:30 14:30 (60 mins)

Main agenda

Next wave immunotherapy: The future including and beyond checkpoints

With immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda having demonstrated an ability to extend survival across heavily pretreated tumor types, all eyes are now looking ahead to how the effect of size and addressable patient populations can be expanded upon. Indeed, a range of modalities have emerged as potential candidates for checkpoint combination regimens, each poised to address “cold” or otherwise IO-resistant patients. Many questions still exist, including which mechanisms will be best suited to unleash the full power of the anticancer immune response, in what patients, and over what time horizons will various developments continue to play out. Join our distinguished panel as we discuss and debate some of the finer points surrounding clinical and commercial issues in oncology and look to achieve a deeper understanding about who and how to achieve relevance in the emerging IO landscape.

  • Moderator Joel Sandler - Associate Principal, Defined Health
  • Panelist Bernd Mühlenweg - Chief Business Officer, Nanobiotix

16:00 17:00 (60 mins)

Main agenda

Developing solutions for pediatric diseases

  • Panelist Elizabeth Aylward - Director, Office of Science-Industry Partnerships, Seattle Children’s Research Institute

17:15 18:15 (60 mins)

Main agenda

Cell and Gene Therapies

14:45 15:45 (60 mins)

Main agenda

What the deals of 2017 mean for 2018

This panel will examine the deal trends of 2017. What are the drivers? Who are the players? What are the structures? Can we expect to see these trends continue into 2018? Join us for a deep dive into the deals of 2017.

  • Moderator David McClain - Principal, ClearView Healthcare Partners
  • Panelist Ron Newbold - VP, Global Scouting, External R&D Innovation, Pfizer
  • Panelist Ben Thorner - Senior VP, Business Development and Licensing, MSD

16:00 17:00 (60 mins)

Main agenda

Building the future of the European public market

The European biotech market has much going for it: strong M&A, strong investment, exciting young companies with the potential for lucrative exits. This session will discuss how the strengths of the industry can be consolidated through the further development of a European public market.

  • Moderator Olivier Litzka - Partner, Edmond de Rothschild Investment Partners

17:15 18:15 (60 mins)

Main agenda

Partner or go it alone?

16:00 16:30 (30 mins)

Main agenda

Break and Breathe

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. 

Open to all. No prerequisites required. Standing and seated positions only.


18:00 18:45 (45 mins)

Main agenda

Champagne reception at EBD Group booth

19:00 22:30 (210 mins)

Main agenda

Evening Networking Reception with Buffet-style Dinner